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Axonal regenerationWhile it is well established that the axons of adult neurons have a lower capacity for regrowth, some regeneration
of certain CNS populations after spinal cord injury (SCI) is possible if their axons are provided with a permissive
substrate, such as an injured peripheral nerve. While some axons readily regenerate into a peripheral nerve
graft (PNG), these axons almost always stall at the distal interface and fail to reinnervate spinal cord tissue. Treat-
ment of the glial scar at the distal graft interface with chondroitinase ABC (ChABC) can improve regeneration, but
most regenerated axons need further stimulation to extend beyond the interface. Previous studies demonstrate
that pharmacologically inhibiting kinesin-5, a motor protein best known for its essential role in mitosis but also
expressed in neurons, with the pharmacological agent monastrol increases axon growth on inhibitory substrates
in vitro. We sought to determine if monastrol treatment after an SCI improves functional axon regeneration.
Animals received complete thoracic level 7 (T7) transections and PNGs and were treated intrathecally with
ChABC and either monastrol or DMSO vehicle. We found that combining ChABC with monastrol signiﬁcantly
enhanced axon regeneration. However, there were no further improvements in function or enhanced c-Fos
induction upon stimulation of spinal cord rostral to the transection. This indicates that monastrol improves
ChABC-mediated axon regeneration but that further treatments are needed to enhance the integration of these
regrown axons.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
While it is well established that adult neurons have a lower capacity
for regrowth, some regeneration of certain CNS populations after SCI is
possible if their axons are providedwith a permissive substrate, such as
an injured peripheral nerve.While some axons readily regenerate into a
PNG, coaxing these same axons to grow beyond the graft has proven to
be a greater challenge. Axons almost always stall at the distal interface
and fail to reinnervate spinal cord tissue. This is thought to be due at
least partly to the inhibitory matrix associated with the glial scar at
the graft–host interface. Cleavage of inhibitory sugar moieties of CSPG
within the scar at the distal PNG–spinal cord interface with ChABC
allows some axons to regenerate out of the graft and re-enter the spinal
cord. The axonal regeneration resulting from this combinatorial
approach is functional (Tomet al., 2009). Despite ChABC, the percentage
of axons exiting the graft is small (b20% of total axons that regenerateiology and Anatomy, Drexel
elphia, PA 19129. Fax: +1 215
. This is an open access article underinto the graft). This suggests that most axons that extend into the PNG
need further stimulation to grow beyond the interface. Thus, while
modulating the inhibitorymatrix of the glial scar promotes some axonal
regeneration, developing additional strategies to improve the axons'
intrinsic abilities to regenerate is necessary to increase the potential
for functional recovery after injury.
The cytoskeleton is essential to the differentiation and growth of the
axon, the regeneration of injured axons, and themotility and navigation
of the growth cone. Microtubules, one component of the axonal cyto-
skeleton, contribute to the structural integrity of axons and also to the
intracellular transport of organelles through their interactions with
motor proteins. Short microtubules move in the axon anterogradely
and retrogradely, with the same forces imposed on the longer microtu-
bules contributing to the structural integrity that regulates whether an
axon grows or retracts (Baas et al., 2006). The anterograde transport
of shortMTs to the growing tip of the axon appears to be amajor driving
force in promoting axonal extension. Thus, augmenting the forces on
microtubules that contribute to axon growth and oppose axon retrac-
tion is a potentially powerful strategy to enhance axon regeneration
after injury.
Interestingly, it was recently discovered that the motor protein
kinesin-5 (also known as Eg5, a motor protein best known for itsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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bules in juvenile axons (Myers and Baas, 2007). Furthermore, inhibition
of kinesin-5 (either pharmacologically with the drug monastrol or with
siRNA) markedly increases the frequency of short microtubule trans-
port and diminishes bouts of axonal retraction, presumably due to the
effects of the kinesin-5 on short and longmicrotubules respectively. Ad-
ditionally, treatment with monastrol, a cell-permeable small molecule
that prevents normal kinesin-5 ATPase activity, allows adult axons to
partially overcome normally inhibitory cues and grow on substrates,
such as CSPG, in vitro (Lin et al., 2011).
In this study,we sought todetermine if these in vitro results translate
to an in vivo setting to improve axonal regeneration beyond a PNG inter-
face that is also treatedwith ChABC. Additionally, wewanted to assess if
enhanced regeneration mediates functional recovery.
Methods and materials
Spinal cord injuries
All procedures complied with Drexel University’s Institutional
Animal Care and Use Committee and National Institutes of Health
guidelines for experimentation with laboratory animals. Adult female
Sprague–Dawley rats (Charles River, 225–250 g) were deeply anesthe-
tized with isoﬂurane. The dorsal surface of the thoracic level 7 (T7) was
exposed by laminectomyand the spinal cordwas completely transected
by aspiration. A heterologous tibial nerve was harvested from a donor
rat that received a tibial nerve cut 1 week prior to harvest. Four
segments of the harvested predegenerated tibial nerve were grafted
into the fresh cavity so that they spanned the lesion. The dura was su-
tured shut using 9-0 sutures. Then, an intrathecal catheter (ReCathCo)
attached to an osmotic minipump (Alzet, model 2002) was placed
subdurally so that the end of the catheter was just rostral to the
distal PNG–host interface. The minipump was ﬁlled with 20 U/mL
ChABC (Amsbio) thermostabilized in trehalose/PBS (Lee et al., 2010)
and either 1 mM monastrol (EMD Biosciences) or DMSO vehicle. To
prevent rejection of the PNG, the recipient animals received daily sub-
cutaneous injections of Cyclosporine A (10 mg/kg, Sandimmune,
Novartis Pharmaceuticals) starting 3 days before the injury and grafting
for the duration of the experiment.
Behavioral testing
Hindlimb function for animals treated with ChABC+ DMSO (n=8)
and ChABC+ monastrol (n=8)was evaluated in an open ﬁeldmeasur-
ing 2.5 × 3 ft using the Basso–Beattie–Bresnahan (BBB) rating scale by
two individuals blinded to the treatment condition prior to injury and
every other week for 13 weeks starting 1 week after the transection
and grafting. The scores of the two groups were compared at each time
point using a Mann–Whitney U test (SPSS).
Electrical stimulation of the PNG
Similar to previously methodology (Tom et al., 2009), at least
13 weeks after the transection and grafting, animals (n= 5 per exper-
imental group) were anesthetized with ketamine and xylazine and the
T4 spinal cord was exposed by laminectomy. A multi-unit electrode
(A4 × 4 3 mm 100-125-177, NeuroNexus) was used to stimulate spinal
cord rostral to the PNG for 1 h (1 mA amplitude, 100 μs pulse duration,
and 50 Hz frequency). Animals were killed and perfused 1 h later with
4% PFA.
Labeling of regenerated axons in PNG
To trace axons that regenerated into the PNG, animals were deeply
anesthetized. At least 13 weeks after the transection and grafting,
the portion of the spinal column containing the lesion was exposedand 10% biotinylated dextran amine (BDA, Invitrogen) was injected
into the PNG using a glass pipette to label regenerating axons [n=3 an-
imals per group] (Tomet al., 2009)]. Animalswere perfusedwith 4% PFA
1 week later.
Histology
Segments of spinal cord containing the PNGs were dissected
and post-ﬁxed overnight in 4% PFA at 4 °C. The tissue then was
cryoprotected in 30% sucrose before sectioning on a cryostat. To visual-
ize BDA-labeled axons in the animals injected with BDA, horizontal
sections (25 μm) were cut in a series of six sets. Sections were blocked
in 5% normal goat serum, 1% bovine serum albumin, 0.1% Triton X-100
in PBS for 1 h at room temperature and then incubated with anti-
GFAP (Dako) overnight at 4 °C. The sections were rinsed in PBS and
incubated in streptavidin–Alexa 488 or goat anti-rabbit Alexa 594
(Invitrogen) overnight at 4 °C. Sections were rinsed in PBS, mounted
onto glass slides, and coverslipped using FluorSave (Calbiochem).
For animals that were electrically stimulated, transverse sections of
spinal cord within 1.5 mm caudal to the distal interface were sectioned
in a series of six, blocked in the same blocking solution described above,
and incubated with an antibody to c-Fos (Abcam, Cambridge, MA). The
sections were rinsed and incubated with goat-anti rabbit Alexa 594
overnight at 4 °C. Sections were rinsed in PBS, mounted onto glass
slides, and coverslipped using FluorSave (Calbiochem).
All sections were imaged using an Olympus BX51 microscope.
Quantiﬁcation
To quantify BDA+ regenerating axons that emerged from PNGs, hor-
izontal sections (ﬁve sections per animal) containing a PNG were used
for image analysis. The number of BDA+ axons located in the PNG just
rostral to and just caudal to the distal interface was counted. The ratio
of number of axons distal to the graft to axons caudal to the graft was
calculated. The ratios of the ChABC + monastrol and ChABC + DMSO
were compared statistically using a Student's t test (SPSS). Signiﬁcance
was determined if p b 0.05.
To quantify the number of c-Fos+ cells after stimulation of the rostral
cord, four transverse sections immediately caudal to the PNG from each
electrophysiologically stimulated animal were imaged. A predetermined
saturation threshold level (MetaMorph, Molecular Devices, Sunnyvale,
CA) was applied to each section to eliminate background or non-speciﬁc
staining. All images were subject to the same saturation threshold. Cells
with c-Fos+nuclei above thresholdwere counted in graymatter ipsilater-
al and contralateral to the graft. The numbers of ipsilateral c-Fos+ nuclei
were statistically compared a Student's t test (SPSS). Signiﬁcance was
determined if p b 0.05.
Results
We wanted to determine if inhibiting kinesin-5 pharmacologically
with monastrol improves the ability of axons to regenerate. To do this,
a PNwas grafted into T7 transection site. The distal interfacewas treated
with ChABC andmonastrol or DMSO vehicle. Three months later, axons
that regenerated into the graftswere labeledwith BDA. In animals treat-
ed with DMSO, some axons were able to cross the distal interface and
extend into caudal spinal cord (Fig. 1A′, arrow, B). However, many
axons did not extend beyond this boundary (arrowheads in Fig. 1A′),
agreeing with previous data indicating that ChABC alone promotes
limited regeneration. Animals treated with monastrol displayed signiﬁ-
cantly enhanced regeneration.Manymore axonswere observed crossing
the distal interface to reinnervate spinal cord (arrows in Fig. 1C, D).
Approximately 57% ± 3.5% of axons present at the distal end of
the PNG were able to extend into GFAP+ rich spinal cord in the
monastrol-treated animals, whereas ~28% ± 8.4% were able to in the
DMSO-treated animals (Fig. 1E, p b 0.05).
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relevance and improved functional recovery, we tested the ability of
these T7 transected rats to locomote in the open ﬁeld. DMSO and
monastrol-treated animals had similar BBB scores at all testing time
points (Fig. 1F). At 2 days after injury, BBB scores for DMSO animals
were 0.25 ± 0.1 and monastrol animals were 0.25 ± 0.1. At 1 week,
BBB scores improved to 0.9 ± 0.3 for DMSO animals and 1.67 ± 1.1
for monastrol animals. The BBB scores continued to improve during
the testing period of 13 weeks: 3 weeks (DMSO: 2.5 ± 0.7; monastrol:Fig. 1.Monastrol treatment enhances regeneration beyonda peripheral nerve graft and through
BDA (green). GFAP+ host astrocytes are in red. Insets are highmagniﬁcation images of boxed reg
failed to extend into caudal spinal cord (arrows; A′). On the other hand, signiﬁcantlymore axon
monastrol treatment. The functional relevance of the axons that regenerated out of the PNG in
scores of both sets of animals improved over time after the injury. However, the scores between
ally, spinal cord rostral to the PNG was electrically stimulated. Though this resulted in the in
difference in the number of c-Fos+ neurons (G). c: caudal; scale bar: 100 μm. *p b 0.03.1.3 ± 0.7); 5 weeks (DMSO: 4.7 ± 1.0; monastrol: 3.4 ± 1.3); 7 weeks
(DMSO: 4.9 ± 1.0; monastrol: 5.0 ± 0.9); 9 weeks (DMSO: 4.75 ± 1.1;
monastrol: 5.0 ± 1.4); and 11 weeks (DMSO: 5.9 ± 1.0; monastrol:
6.9 ± 0.4). At 13 weeks, scores for both groups (DMSO: 6 ± 0.8;
monastrol: 7.1 ± 0.1) indicated that the animals were capable of exten-
sive movement of the joints at the hip, knee, and ankle. Thus, both co-
horts of ChABC-treated animals were better able to locomote in the
open-ﬁeld. However, the monastrol treatment did not further improve
the ability of completely transected ChABC-treated animals to locomote.a chondroitinase-treated glial scar. Axons that regenerated into the graftwere labeledwith
ions.While some axons regenerated through the ChABC-treated interface (D),most axons
s emerged from the graft (arrowheads, B′, D, E) to reinnervate spinal cord tissue following
the ChABC and DMSO or monastrol-treated animals was examined. In the BBB test (F), the
the two groups were not signiﬁcantly different at any of the tested time points. Addition-
duction of c-Fos in neurons caudal to the injury in both groups, there was no signiﬁcant
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wewanted to further assess integration of the regenerated axons by ex-
amining the extent of c-Fos induction in spinal cord caudal to the PNG
upon stimulation of spinal cord rostral to the PNG. We found that
there was no signiﬁcant difference in the numbers of c-Fos+ neurons
(Fig. 1G). DMSO-treated animals had 8.5 ± 1.4 c-Fos+ neurons per
section while monastrol-treated animals had 16.0 ± 4.7. This indicates
that monastrol-mediated axon regeneration did not integrate and
form functional synapses upon distal neurons.
Discussion
Although ChABC-mediated digestion of CSPG, a major component of
the inhibitory matrix of the glial scar, improves the ability of axons to
regenerate, the resulting regeneration is modest. Thus, more robust
regeneration may be limited by the meager intrinsic ability of mature
axons to extend. Becausemicrotubules play a critical role in axon exten-
sion, we sought to determine if inhibiting kinesin-5 in injured axons
pharmacologically with monastrol will help overcome this barrier to
result in improved regeneration beyond a PNG–cord interface also
treated with ChABC. We found that monastrol indeed improved ana-
tomical regeneration. However, these axons did not appear to integrate
into circuitry. Themonastrol andDMSO treated animals had similar BBB
scores. Furthermore, we did not observe any differences in c-Fos induc-
tion in neurons upon stimulation of spinal cord rostral to the graft.
Embryonic neurons are capable of signiﬁcantly better axonal growth
than more mature axons. This is probably due to a combination of
changes that are extrinsic and intrinsic to the neuron. In particular, the
expression of several proteins that help regulate protein synthesis,
such as KLF (Krüppel-like factor) and mTOR (mammalian target of
rapamycin), are developmentally regulated. Proteins associated with
the axonal cytoskeleton are likely targets of this transcriptional control
(Blackmore, 2012).
We chose to focus on monastrol to affect microtubules, one compo-
nent of the axon cytoskeleton, becausewewere building upon previous
work demonstrating thatmonastrol treatment to pharmacologically in-
hibit kinesin-5 activity in neurites in vitro improves growth, including
on inhibitory CSPG substrates (Lin et al., 2011). One beneﬁt of using
monastrol, a pharmacological agent, is that we canmore closely control
how longwe affect kinesin-5 thanwith other techniques, such as genetic
knockdown.Moreover, pharmacologically inhibiting kinesin-5 activity is
currently being tested as an anti-cancer treatment in several clinical
trials. Thus, in the future, we may build upon the data presented in
this manuscript to determine if other similarly acting drugs are more
effective than monastrol at promoting growth.
It is important to note that other drugs that affect microtubule
behaviors have also been shown to promote axonal extension. The
microtubule-stabilizer taxol (paclitaxel) has been shown to promote
axonal regeneration (Hellal et al., 2011; Sengottuvel et al., 2011). NAP,
a short, 8-amino acid peptide, is thought to protect microtubules from
degradation. Interestingly, NAP has been demonstrated to increase
axonal extension in culture (Sudo and Baas, 2011). F05 is a triazine
that was shown to increase dynamic microtubules and increase axonal
regeneration in vitro on inhibitory substrates and in vivo in dorsal
column and optic nerve injury models (Hellal et al., 2011). While how
each of these compounds interacts withmicrotubules is not completely
understood, it is clear that they affect microtubule behaviors via differ-
ent mechanisms. It is not yet known if promoting microtubule stability
or some other, subtler effect on microtubule would best promote
outgrowth.
Unlike drugs such as taxol or F05, monastrol would not be expected
to add to or stabilize microtubule mass, but rather shift the balance of
forces on existing microtubules. Given that kinesin-5 is important for
growth cone navigation (Nadar et al., 2008), it is perhaps not surprising
that the axons in our study could not reintegrate to elicit functional
recovery. One possibility is that a better functional outcome could beachieved by optimizing the exposure of the injury site to monastrol
for a more limited period of time.
Our focus was on affecting microtubules to enhance regrowth of in-
jured axons, soweused a complete transectionmodel, the bestmodel to
assess true regeneration. However, microtubules are not only important
for axon extension; dynamic microtubules are also critical for the initia-
tion of collateral branch points. In fact, inhibiting kinesin-5 activity in-
creases neuritic branching in vitro (Myers and Baas, 2007). Interestingly,
collateral sprouting has been associated with signiﬁcant functional
improvements. It would be interesting to determine if a microtubule-
focused strategy that increases short microtubule transport (e.g. with
monastrol) would also improve functionally compensatory collateral
sprouting in an incomplete injury model (i.e. contusion or hemisection).
An earlier concern about the use of kinesin-5 inhibitors to augment
regeneration of injured adult axonswaswhether adult neurons express
enough kinesin-5 for its inhibition to elicit a notable effect. Our results
suggest that they do. It is also possible that monastrol affects microtu-
bules in glia, although not much is known regarding kinesin-5 expres-
sion levels in astrocytes or Schwann cells. Microtubule stabilization via
taxol administration diminishes astrocytic migration in vitro and has
been suggested to decrease glial scarring after injury (Hellal et al.,
2011; Sengottuvel et al., 2011). Furthermore, Schwann cells and astro-
cytes have “unfavorable” interactions upon their contacting each
other, resulting in the formation of sharp boundaries between them
that have been linked to regenerative failure (Deng et al., 2008). In
our study, we did not notice any appreciable difference in the astrocytic
response at the graft interface between monastrol and DMSO treated
animals (note similar GFAP expression levels in Fig. 1a and c). Thus,
we do not believe that the enhanced regeneration observed in the
monastrol-treated animals is mediated by altering or attenuating the
gliotic response at the injury site.
Although multiple groups, including ours, have shown that an
increase in the number of axons into a denervated region after injury
can correlate with improved function, it is clear that promoting axon
regeneration alone is not always sufﬁcient to improve function. In
both this and previous studies, the presence of more ﬁbers does not
always translate into improved function. Thus, additional strategies,
such as the addition of exogenous factors to promote the integration
of regenerated axons or rehabilitation to shape functional synapse
formation on appropriate targets need to be utilized.
While we did not directly assess which population of ﬁbers regener-
ate out of the graft, it is likely that they are of propriospinal and
not supraspinal origin. It was previously demonstrated that the closer
the injury is to the soma, the greater the increase in regeneration-
associated gene expression. As such, supraspinal neurons, e.g. the retic-
ular formation and the red nucleus, regenerate more readily into PNs
grafted into a cervical injury site than a thoracic site; grafts placed into
thoracic level injuries contain mainly regenerating axons from
propriospinal neurons (Richardson et al., 1984). Thus, we can expect
that in these experiments in which PNs were inserted into T7Tx sites,
primarily propriospinal axons and not descending axons regenerate
into the PNGs.
One thing to note is that we observed improved BBB scores over
time in both the DMSO + ChABC and monastrol + ChABC groups. It is
possible that the improvement is due to regeneration of injured ﬁbers.
It is also possible that the improvement is related to neurotrophins
secreted from the Schwann cells in the PNG. Neurotrophins, such as
brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3),
can promote some degree of locomotor recovery in the absence of any
axon regeneration through a lesion site (Boyce et al., 2007). As we did
not resect the spinal cord above the T7 transection site, it is not clear
what the mechanism of this improvement is. We will begin to explore
the sources of this recovery in future studies.
In conclusion, pharmacologically inhibiting kinesin-5withmonastrol
signiﬁcantly enhanced the ability of axons to regenerate out of a PNG
to reinnervate caudal spinal cord after injury. However, this increased
176 C. Xu et al. / Experimental Neurology 263 (2015) 172–176anatomical regeneration did not improve functional recovery. Thus,
monastrol treatment alone is not sufﬁcient to promote functional axon
regeneration but has the potential to be a key component of a combina-
torial strategy.
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